CN102166286B - Medicine for treating osteoporosis - Google Patents
Medicine for treating osteoporosis Download PDFInfo
- Publication number
- CN102166286B CN102166286B CN201110103098XA CN201110103098A CN102166286B CN 102166286 B CN102166286 B CN 102166286B CN 201110103098X A CN201110103098X A CN 201110103098XA CN 201110103098 A CN201110103098 A CN 201110103098A CN 102166286 B CN102166286 B CN 102166286B
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- rhizoma atractylodis
- oil
- atractylodis oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a traditional Chinese medicine, in particular to a medicine for treating osteoporosis, which is prepared by active pharmaceutical ingredients according to the following parts by weight: 3-5 parts of atractylis oil, 10-15 parts of raidx astragali, 10-15 parts of codonopsis pilosula, 10-15 parts of musk, 10-15 parts of toad, 10-15 parts of polygonum multiflorum thumb, 10-15parts of resina draconis, 10-15 parts of oyster and 10-15 parts of pearl, wherein the atractylis oil is prepared by the following steps: taking and soaking atractylis medicinal material by adding water, conducting distillation and extraction with steam, and then obtaining an oily matter which is the atractylis oil through separation. The medicine has the beneficial effects that the medicine is prepared by the atractylis oil and other eight traditional Chinese medicines, wherein the oyster and the pearl can provide a basic source of calcium to increase the absorption of calcium and regulate calcium metabolism by matching with other traditional Chinese medicines, and the medicine has very good curative effect in the treatment of the osteoporosis; moreover, all the medicaments are traditional Chinese medicine ingredients which do not have toxic side effect to a human body, and can not cause harm or drug dependence after long-term use.
Description
Technical field
The present invention relates to a kind of Chinese medicine, particularly a kind of medicine of treating osteoporosis.
Background technology
Osteoporosis (osteopsis is called for short OPS) is the common senile disease that a kind of fibre structure with low bone amount and osseous tissue deteriorates to characteristic; Mainly showing as fracture and invasion and attack vertebra and cause complication such as lumbar and back pain and height cripetura, is a kind of serious disabling condition.
At present, aspect traditional Chinese medical herbal treatment, mainly through the kidney invigorating, replenish the calcium and treat osteoporosis, but curative effect is not remarkable.
Summary of the invention
The object of the present invention is to provide the medicine of the treatment osteoporosis that a kind of therapeutic effect is good, toxic and side effects is little.
The invention discloses a kind of medicine of treating osteoporosis,
A kind of medicine of treating osteoporosis is processed by following bulk drugs: Rhizoma Atractylodis oil 3-5 part, Radix Astragali 10-15 part, Radix Codonopsis 10-15 part; Moschus 10-15 part, Bufo siccus 10-15 part, Radix Polygoni Multiflori 10-15 part; Sanguis Draxonis 10-15 part, Concha Ostreae 10-15 part, Margarita 10-15 part;
Said Rhizoma Atractylodis oil is to make through following steps: get the Rhizoma Atractylodis medical material, soak, water vapour distillation separates to such an extent that grease is Rhizoma Atractylodis oil.
With Rhizoma Atractylodis oil with beta-schardinger dextrin-according to weight ratio 1:10 inclusion, Rhizoma Atractylodis oil β-cyclodextrin inclusion complex; Take by weighing the Radix Astragali, Radix Codonopsis, Moschus, Bufo siccus, Radix Polygoni Multiflori, Sanguis Draxonis, Concha Ostreae, Margarita mixes, and pulverizes with super micron mill, crosses 200 mesh sieves, with Rhizoma Atractylodis oil β-cyclodextrin inclusion complex mix homogeneously, incapsulates, and is prepared into soft capsule dosage form.
The cause of disease of osteoporosis is commonly considered as because bone is rebuild the not enough balance of circulation; Promptly broken bone process is slightly more than osteogenetic process; Cause the bone amount to reduce, and the main cause that causes this abnormal bone metabolism is age ageing, cause endocrine disturbance's factors such as nutritional labeling Deficiency of Intake, hypomotility, parathyroid hormone surplus and calcitonin, active form vitamin D, estrogen deficiency such as calcium.
Beneficial effect: medicine of the present invention is processed by Rhizoma Atractylodis oil and other eight flavors Chinese medicine, and Concha Ostreae and Margarita can provide basic calcium source, match with other each Chinese medicine, can increase the absorption of calcium, regulate the metabolism of calcium, and the treatment osteoporosis is had better curative effect; And medicine of the present invention is Chinese medicine ingredients, and to the human non-toxic side effect, long-term eating can not produce harm yet, can not produce drug dependence.
The specific embodiment
Embodiment 1
1. get Rhizoma Atractylodis medical material coarse granule 100kg, add 4 times of water gagings, soaked 2 hours, water vapour distillation 7 hours makes Rhizoma Atractylodis oil 3kg with separated form water;
2. get above-mentioned Rhizoma Atractylodis oil with beta-schardinger dextrin-according to weight ratio 1:10 inclusion, Rhizoma Atractylodis oil β-cyclodextrin inclusion complex;
3. take by weighing Radix Astragali 10kg respectively, Radix Codonopsis 10kg, Moschus 10kg, Bufo siccus 10kg, Radix Polygoni Multiflori 10kg; Sanguis Draxonis 10kg, Concha Ostreae 10kg, Margarita 10kg mixes, and pulverizes with super micron mill; Cross 200 mesh sieves,, incapsulate every 0.5g with Rhizoma Atractylodis oil β-cyclodextrin inclusion complex mix homogeneously.
Usage and consumption: oral, one time 1,2 times on the one.
Embodiment 2
1. get Rhizoma Atractylodis medical material coarse granule 130kg, add 4 times of water gagings, soaked 2 hours, water vapour distillation 7 hours makes Rhizoma Atractylodis oil 5kg with separated form water;
2. get above-mentioned Rhizoma Atractylodis oil with beta-schardinger dextrin-according to weight ratio 1:10 inclusion, Rhizoma Atractylodis oil β-cyclodextrin inclusion complex;
3. take by weighing Radix Astragali 15kg respectively, Radix Codonopsis 15kg, Moschus 15kg, Bufo siccus 15kg, Radix Polygoni Multiflori 15kg; Sanguis Draxonis 15kg, Concha Ostreae 15kg, Margarita 15kg mixes, and pulverizes with super micron mill; Cross 200 mesh sieves,, incapsulate every 0.5g with Rhizoma Atractylodis oil β-cyclodextrin inclusion complex mix homogeneously.
Usage and consumption: oral, one time 1,2 times on the one.
Medicine of the present invention is summed up the osteoporosis clinical treatment
Sufferers of osteoporosis face is totally 100 examples, all from certain inpatient of hospital and part clinic case.Be divided into treatment group and matched group at random.Wherein, 50 examples are organized in treatment, male's 31 examples, women's 19 examples, 51-86 years old ages, 66 years old mean age.Matched group 50 examples, male's 28 examples, women's 22 examples, 50-85 years old ages, 67 years old mean age.No difference of science of statistics between two groups of general clinical datas.
1, Therapeutic Method
Treatment group: the soft capsule of the embodiment of the invention 2 preparations.
Method of administration: oral, each 1, every day 2 times, 1 month is 1 course of treatment, totally 3 courses of treatment.
Matched group: the Rhizoma Atractylodis oil soft capsule, every contains Rhizoma Atractylodis oil 0.1g.
Method of administration: oral each 1, every day 2 times, 1 month is 1 course of treatment, takes continuously 3 months.
2, result: two groups of total effective rates to senile osteoporosis, see table 1.
Table 1 liang group is to the total effective rate of senile osteoporosis
Total effective rate is (produce effects number+very imitate number)/total routine number * 100%
Visible by table 1, treatment group produce effects 36% very imitates 52%; Total effective rate 88%; Matched group produce effects 30% very imitates 46%, total effective rate 76%; Statistical procedures no significant difference between two groups explains that the capsule that comprises Rhizoma Atractylodis oil and other raw materials of the present invention will get well much the therapeutic effect of treatment senile osteoporosis than Rhizoma Atractylodis oil capsule.
3, the therapeutic effect of symptoms
Two groups of curative effects to symptoms such as lumbago and backache arthralgia are seen table 2.
Table 2 liang group is to the Comparison of therapeutic table of symptoms such as lumbago and backache arthralgia
Visible by table 2, the treatment group is respectively 100%, 85.71% to the effective percentage of lumbago and backache, arthralgia, tenderness
With 75.00%, all there is not significant difference through statistical procedures greater than between 94.29%, 73.33% and 71.43%, two group of the effective percentage of matched group, explain that soft capsule of the present invention more can effectively improve senile osteoporosis patient's clinical symptoms than Rhizoma Atractylodis oil soft capsule.
4, the contrast of bone density before and after the medication
The bone density contrast table is seen table 3 before and after the medication.
Bone density contrast table before and after the table 3 liang group medication
Find out the treatment group with respect to matched group by table 3, improve the better effects if of bone density.
Blood, routine urinalysis before and after medicine of the present invention is taken medicine, the platelet value, glucose in urine, liver function, renal function etc. are normal, obvious adverse reaction do not occur, and visible medicine of the present invention has safety, efficient, low toxicity, stable characteristics to the treatment osteoporosis.
Claims (2)
1. a medicine of treating osteoporosis is characterized in that being processed by following bulk drugs: Rhizoma Atractylodis oil 3-5 part, Radix Astragali 10-15 part, Radix Codonopsis 10-15 part; Moschus 10-15 part, Bufo siccus 10-15 part, Radix Polygoni Multiflori 10-15 part; Sanguis Draxonis 10-15 part, Concha Ostreae 10-15 part, Margarita 10-15 part;
Said Rhizoma Atractylodis oil is to make through following steps: get the Rhizoma Atractylodis medical material, soak, water vapour distillation separates to such an extent that grease is Rhizoma Atractylodis oil.
2. the medicine of treatment osteoporosis according to claim 1 is characterized in that Rhizoma Atractylodis oil with beta-schardinger dextrin-according to weight ratio 1:10 inclusion, Rhizoma Atractylodis oil β-cyclodextrin inclusion complex; Take by weighing the Radix Astragali, Radix Codonopsis, Moschus, Bufo siccus, Radix Polygoni Multiflori, Sanguis Draxonis, Concha Ostreae, Margarita mixes, and pulverizes with super micron mill, crosses 200 mesh sieves, with Rhizoma Atractylodis oil β-cyclodextrin inclusion complex mix homogeneously, incapsulates, and is prepared into soft capsule dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110103098XA CN102166286B (en) | 2011-04-25 | 2011-04-25 | Medicine for treating osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110103098XA CN102166286B (en) | 2011-04-25 | 2011-04-25 | Medicine for treating osteoporosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102166286A CN102166286A (en) | 2011-08-31 |
| CN102166286B true CN102166286B (en) | 2012-05-30 |
Family
ID=44487729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110103098XA Expired - Fee Related CN102166286B (en) | 2011-04-25 | 2011-04-25 | Medicine for treating osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102166286B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1121417A (en) * | 1995-01-27 | 1996-05-01 | 严镇琪 | Pearl oyster preparation for supplement of calcium |
| CN101637591A (en) * | 2008-08-01 | 2010-02-03 | 梁振兴 | Medicinal composition with functions of strengthening tendons and bones and reviving joints and preparation method |
-
2011
- 2011-04-25 CN CN201110103098XA patent/CN102166286B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1121417A (en) * | 1995-01-27 | 1996-05-01 | 严镇琪 | Pearl oyster preparation for supplement of calcium |
| CN101637591A (en) * | 2008-08-01 | 2010-02-03 | 梁振兴 | Medicinal composition with functions of strengthening tendons and bones and reviving joints and preparation method |
Non-Patent Citations (1)
| Title |
|---|
| 高学敏等.中医预防及改善骨质疏松系列保健食品的研发思路及范例介绍.《中国骨质疏松杂志》.2006,第12卷(第04期),415-423. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102166286A (en) | 2011-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101843787A (en) | Chinese medicament for treating benign prostatic hyperplasiabrain | |
| CN101062080B (en) | Medicinal composition for relieving fatigue and preparing process thereof | |
| CN101293065B (en) | Biological proprietary Chinese medicine for preventing and treating diabetes | |
| CN108938989B (en) | Fennel essence-coated bone-strengthening powder for treating osteoporosis | |
| CN104013817A (en) | Conic gymnadenia tuber-sealwort-radix polygonati officinalis preparation and production method thereof | |
| CN102973758A (en) | Traditional Chinese medicine composition for treating depression | |
| CN105194301A (en) | Traditional Chinese medicine preparation for treating chronic cardiac failure | |
| CN109453317A (en) | A kind of anaesthetic and its preparation process for strengthening by means of tonics | |
| CN101843747B (en) | Chinese medicament for treating rheumatoid arthritis | |
| CN104548049A (en) | Traditional Chinese medicine composition for treating senile osteoporosis and preparation method thereof | |
| CN102166286B (en) | Medicine for treating osteoporosis | |
| CN106880756A (en) | For hypokinetic Chinese medicine composition of therapeutic and preparation method thereof | |
| CN103432208A (en) | Medicinal composition containing cordyceps sinensis | |
| CN100467043C (en) | Chinese medicine for treating osteoporosis and its preparation | |
| CN103272159A (en) | Chinese herbal preparation used for treating consumptive disease and preparation method thereof | |
| CN105368672A (en) | Health-care wine containing phellinus | |
| CN106511549A (en) | Traditional Chinese medicine composition containing millettia specisoa and preparation method of traditional Chinese medicine composition | |
| CN101843740B (en) | Chinese medicament for treating climacteric syndromes | |
| CN101843718B (en) | Chinese medicament for treating lupus erythematosus | |
| CN114306497B (en) | Traditional Chinese medicine composition for treating kidney deficiency and blood stasis type osteoporosis, preparation and application | |
| CN102657716A (en) | Anti-aging traditional Chinese medicine composition and preparation method thereof | |
| CN101843705B (en) | Chinese medicament for treating lupus erythematosus | |
| CN105796860A (en) | Quick-acting bone setting Yi medicine | |
| CN107296906A (en) | Chinese medicine composition and its application in pneumonia treatment | |
| CN101843806B (en) | Chinese medicament for treating climacteric syndromes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: YAN SHUXIN Free format text: FORMER OWNER: LI QIURONG Effective date: 20120315 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yan Shucuan Inventor after: Chen Shangya Inventor after: Yan Xingjian Inventor after: Wang Ji Inventor after: Chen Zeyu Inventor before: Li Qiurong |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250000 JINAN, SHANDONG PROVINCE TO: 250012 JINAN, SHANDONG PROVINCE Free format text: CORRECT: INVENTOR; FROM: LI QIURONG TO: YAN SHUXIN CHEN SHANGYA YAN XINGJIAN WANG JI CHEN ZEYU |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20120315 Address after: 250012 Lixia District, 107 west Wenhua Road, Qilu Hospital, Shandong University Applicant after: Yan Shucuan Address before: 250000 Shandong Province Flyover District of Ji'nan City, Phoenix Road District No. 12 building 12 unit 301 Applicant before: Li Qiurong |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120530 Termination date: 20130425 |